CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 16 enrolled
Drug / intervention
[18F]T807 ([18F]MNI-777)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02103894
NCT02103894Phase 1Completed
CompareCT.gov

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Clinically Diagnosed Tauopathies in Comparison to Healthy Subjects

Molecular NeuroImaging·interventional·Posted Apr 4, 2014·Updated Dec 16, 2016

In Brief

A Phase 1 clinical trial evaluating [18F]T807 ([18F]MNI-777) for Alzheimer's Disease (AD) and 6 related conditions. Completed, enrolled 16 participants across 1 site.

Detailed Summary

The goal of this study is to assess \[18F\]MNI-777 PET imaging as a tool to detect tau pathology in the brain of individuals who carry a clinical diagnosis of a tauopathy, including: Alzheimer's Disease (AD),Parkinson's disease (PD) Progressive Supranuclear Palsy (PSP), chronic traumatic encephalopathy (CTE) and Frontal Temporal Dementia (FTD) and age- and gender-matched healthy subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease (AD), Parkinson's Disease (PD), Chronic Traumatic Encephalopathy (CTE), Progressive Supranuclear Palsy (PSP), Frontal Temporal Dementia (FTD), Pick's Disease, Tauopathies
CountriesUnited States
CollaboratorsInstitute for Neurodegenerative Disorders

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 4, 2014
Enrollment StartFeb 1, 2014
Primary CompletionAug 1, 2016
Study CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 12.2 years ago

Interventions

[18F]T807 ([18F]MNI-777)drug

All enrolled subjects will undergo an \[18F\]MNI-777 PET imaging visit. For individuals with AD or CTE, \[18F\]florbetapir imaging may also be performed to serve as a means of correlating disease severity by evaluating the relationship of β-amyloid uptake (measured by \[18F\]florbetapir imaging) and tau protein uptake (measured by \[18F\]MNI-777 PET imaging). For individuals with Parkinsonian symptoms, \[123I\]β-CIT SPECT imaging may be performed to evaluate for a reduction in dopamine transporter uptake.